Literature DB >> 28463167

Exploring the Margin Recipe for Online Adaptive Radiation Therapy for Intermediate-Risk Prostate Cancer: An Intrafractional Seminal Vesicles Motion Analysis.

Yang Sheng1, Taoran Li2, W Robert Lee3, Fang-Fang Yin4, Q Jackie Wu4.   

Abstract

PURPOSE: To provide a benchmark for seminal vesicle (SV) margin selection to account for intrafractional motion and to investigate the effectiveness of 2 motion surrogates in predicting intrafractional SV coverage. METHODS AND MATERIALS: Fifteen prostate patients were studied. Each patient had 5 pairs (1 patient had 4 pairs) of pretreatment and posttreatment cone beam CTs (CBCTs). Each pair of CBCTs was registered on the basis of prostate fiducial markers. All pretreatment SVs were expanded with 1-, 2-, 3-, 4-, 5-, and 8-mm isotropic margins to form a series of planning target volumes, and their intrafractional coverage to the posttreatment SV determined the "ground truth" for exact coverage. Two motion surrogates, the center of mass (COM) and the border of contour, were evaluated by the use of Pearson product-moment correlation coefficient and exponential fitting for predicting SV underdosage. Action threshold of each surrogate was calculated. The margin for each surrogate was calculated according to a traditional margin recipe.
RESULTS: Ninety-five percent posttreatment SV coverage was achieved in 9%, 53%, 73%, 86%, 95%, and 97% of fractions with 1-, 2-, 3-, 4-, 5-, and 8-mm margins, respectively. The 5-mm margins provided 95% intrafractional SV coverage in over 90% of fractions. The correlation between the COM and border was weak, moderate, and strong in the left-right (L-R), anterior-posterior (A-P), and superior-inferior (S-I) directions, respectively. Exponential fitting gave the underdosage threshold of 4.5 and 7.0 mm for the COM and border. The Van Herk margin recipe recommended 0-, 0.5-, and 0.8-mm margins in the L-R, A-P, and S-I directions based on the COM, and 1.2-, 3.9-, and 2.5-mm margins based on the border.
CONCLUSIONS: Five-millimeter isotropic margins for the SV constitute the minimum required to mitigate the intrafractional motion. Both the COM and the border are acceptable predictors for SV underdosage with 4.5- and 7.0-mm action threshold. Traditional margin based on the COM or border underestimates the margin.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28463167     DOI: 10.1016/j.ijrobp.2017.02.089

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Magnetic resonance imaging-guided radiotherapy for intermediate- and high-risk prostate cancer: Trade-off between planning target volume margin and online plan adaption.

Authors:  Shyama U Tetar; Anna M E Bruynzeel; Lisa Verweij; Omar Bohoudi; Berend J Slotman; Tezontl Rosario; Miguel A Palacios; Frank J Lagerwaard
Journal:  Phys Imaging Radiat Oncol       Date:  2022-07-03

2.  Outlier identification in radiation therapy knowledge-based planning: A study of pelvic cases.

Authors:  Yang Sheng; Yaorong Ge; Lulin Yuan; Taoran Li; Fang-Fang Yin; Qingrong Jackie Wu
Journal:  Med Phys       Date:  2017-09-30       Impact factor: 4.071

3.  Dosimetric impact of intra-fraction prostate motion under a tumour-tracking system in hypofractionated robotic radiosurgery.

Authors:  Yuhei Koike; Iori Sumida; Hirokazu Mizuno; Hiroya Shiomi; Keita Kurosu; Seiichi Ota; Yasuo Yoshioka; Osamu Suzuki; Keisuke Tamari; Kazuhiko Ogawa
Journal:  PLoS One       Date:  2018-04-05       Impact factor: 3.240

4.  Quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer.

Authors:  Yoshiko Doi; Yuji Murakami; Nobuki Imano; Yuki Takeuchi; Ippei Takahashi; Ikuno Nishibuchi; Tomoki Kimura; Yasushi Nagata
Journal:  PLoS One       Date:  2018-06-11       Impact factor: 3.240

5.  Incorporating Case-Based Reasoning for Radiation Therapy Knowledge Modeling: A Pelvic Case Study.

Authors:  Yang Sheng; Jiahan Zhang; Chunhao Wang; Fang-Fang Yin; Q Jackie Wu; Yaorong Ge
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

6.  Analysis of intra-fraction prostate motion and derivation of duration-dependent margins for radiotherapy using real-time 4D ultrasound.

Authors:  Eric Pei Ping Pang; Kellie Knight; Qiao Fan; Sheena Xue Fei Tan; Khong Wei Ang; Zubin Master; Wing-Ho Mui; Ronnie Wing-Kin Leung; Marilyn Baird; Jeffrey Kit Loong Tuan
Journal:  Phys Imaging Radiat Oncol       Date:  2018-03-28

7.  Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.

Authors:  Gamze Ugurluer; Banu Atalar; Teuta Zoto Mustafayev; Gorkem Gungor; Gokhan Aydin; Meric Sengoz; Ufuk Abacioglu; Mustafa Bilal Tuna; Ali Riza Kural; Enis Ozyar
Journal:  Br J Radiol       Date:  2020-10-29       Impact factor: 3.039

8.  Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer.

Authors:  Rosario Mazzola; Gianluisa Sicignano; Francesco Cuccia; Claudio Vitale; Michele Rigo; Niccolò Giaj-Levra; Luca Nicosia; Vanessa Figlia; Francesco Ricchetti; Giorgio Attinà; Edoardo Pastorello; Antonio De Simone; Davide Gurrera; Stefania Naccarato; Ruggero Ruggieri; Filippo Alongi
Journal:  Br J Radiol       Date:  2021-07-20       Impact factor: 3.629

9.  Variations of MRI-assessed peristaltic motions during radiation therapy.

Authors:  Farshad Mostafaei; An Tai; Eenas Omari; Yingqiu Song; James Christian; Eric Paulson; William Hall; Beth Erickson; X Allen Li
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

10.  Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis.

Authors:  Flora Goupy; Stéphane Supiot; David Pasquier; Igor Latorzeff; Ulrike Schick; Erik Monpetit; Geoffrey Martinage; Chloé Hervé; Bernadette Le Proust; Joel Castelli; Renaud de Crevoisier
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.